The start of a New Year is a good time to take stock of where we’ve come from and where we’re going in the fast-paced world of oncology new product development.
Upregulation doesn’t always mean a protein is a valid target, but in some cases it just might…
In this latest post, we’re revisiting T cell immunoglobulin and mucin domain-containing protein 3 – or TIM-3 in short – and taking a closer look at the evolving competitive landscape in this niche.
One company targeting it is Novartis, who have an anti-TIM–3 antibody MBG453 in development. In this post we have an expert interview with a scientist who is a pioneer in the emerging field of TIM-3 biology.
There’s also a review of some of the recent important scientific papers on TIM-3 biology, as well as commentary on data presented at ASH19 that we expect may feature in presentations at JPM20 next week, not to mention be the focus of future interim updates should the data turn out to show some promise in certain settings.
If you have an interest in targeting novel immune checkpoints and want to find out more about where the field is at with TIM-3, then this post is for you.
Curious to find out more about our latest oncology coverage and get a heads up on additional insights from our latest thought leader interview, analysis, and commentary? Subscribers can log-in or you can click to gain access to BSB Premium Content.
Following the success of anti-CTLA4 and PD(L)1 therapies over the last five years or so, there is much time and attention being focused on addressing a key question, namely – what’s the next viable checkpoint target?
There are quite a few possibilities emerging, although to be fair, some of them will no doubt go by the wayside over the next year or two. There has already been quite a bit of attrition since 2015/16. Figuring out which ones will be a target versus being a useful marker is also an important aspect of new product development.
Competition is a fine thing – as long as they’re going in the direction you want to go.
For most of our ASCO coverage over the last few years we have tended to include a variety of approaches in the pre-conference Preview series that can run from a tumour type, a up and coming modality, an emerging target, and various other ways of looking at or making sense of the sea of data.
Here, we take a look at an IO target that is receiving much interest and explore what we know and where this might be headed… and ask whether the early promise is living up to the billing in practice?
To learn more from our latest conference coverage and oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.